Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients

Abstract Background The positron emission tomography (PET) ligand 68Ga-Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA-11) targets the prostate-specific membrane antigen (PSMA), upregulated in prostate cancer cells. Although 68Ga-PSMA-11 PET is widely used in research and clinical practice, full kinetic modeli...

Full description

Bibliographic Details
Main Authors: Anna Ringheim, Guilherme de Carvalho Campos Neto, Udunna Anazodo, Lumeng Cui, Marcelo Livorsi da Cunha, Taise Vitor, Karine Minaif Martins, Ana Cláudia Camargo Miranda, Marycel Figols de Barboza, Leonardo Lima Fuscaldi, Gustavo Caserta Lemos, José Roberto Colombo Junior, Ronaldo Hueb Baroni
Format: Article
Language:English
Published: SpringerOpen 2020-02-01
Series:EJNMMI Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13550-020-0594-6
id doaj-cc1b32cd51e34221b7627c91ee80898d
record_format Article
spelling doaj-cc1b32cd51e34221b7627c91ee80898d2020-11-25T01:46:38ZengSpringerOpenEJNMMI Research2191-219X2020-02-0110111010.1186/s13550-020-0594-6Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patientsAnna Ringheim0Guilherme de Carvalho Campos Neto1Udunna Anazodo2Lumeng Cui3Marcelo Livorsi da Cunha4Taise Vitor5Karine Minaif Martins6Ana Cláudia Camargo Miranda7Marycel Figols de Barboza8Leonardo Lima Fuscaldi9Gustavo Caserta Lemos10José Roberto Colombo Junior11Ronaldo Hueb Baroni12Hospital Israelita Albert EinsteinHospital Israelita Albert EinsteinLawson Health Research Institute, St Joseph’s Health CareDivision of Biomedical Engineering, University of SaskatchewanHospital Israelita Albert EinsteinHospital Israelita Albert EinsteinHospital Israelita Albert EinsteinHospital Israelita Albert EinsteinHospital Israelita Albert EinsteinHospital Israelita Albert EinsteinHospital Israelita Albert EinsteinHospital Israelita Albert EinsteinHospital Israelita Albert EinsteinAbstract Background The positron emission tomography (PET) ligand 68Ga-Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA-11) targets the prostate-specific membrane antigen (PSMA), upregulated in prostate cancer cells. Although 68Ga-PSMA-11 PET is widely used in research and clinical practice, full kinetic modeling has not yet been reported nor have simplified methods for quantification been validated. The aims of our study were to quantify 68Ga-PSMA-11 uptake in primary prostate cancer patients using compartmental modeling with arterial blood sampling and to validate the use of standardized uptake values (SUV) and image-derived blood for quantification. Results Fifteen patients with histologically proven primary prostate cancer underwent a 60-min dynamic 68Ga-PSMA-11 PET scan of the pelvis with axial T1 Dixon, T2, and diffusion-weighted magnetic resonance (MR) images acquired simultaneously. Time-activity curves were derived from volumes of interest in lesions, normal prostate, and muscle, and mean SUV calculated. In total, 18 positive lesions were identified on both PET and MR. Arterial blood activity was measured by automatic arterial blood sampling and manual blood samples were collected for plasma-to-blood ratio correction and for metabolite analysis. The analysis showed that 68Ga-PSMA-11 was stable in vivo. Based on the Akaike information criterion, 68Ga-PSMA-11 kinetics were best described by an irreversible two-tissue compartment model. The rate constants K 1 and k 3 and the net influx rate constants K i were all significantly higher in lesions compared to normal tissue (p < 0.05). K i derived using image-derived blood from an MR-guided method showed excellent agreement with K i derived using arterial blood sampling (intraclass correlation coefficient = 0.99). SUV correlated significantly with Ki with the strongest correlation of scan time-window 30–45 min (rho 0.95, p < 0.001). Both K i and SUV correlated significantly with serum prostate specific antigen (PSA) level and PSA density. Conclusions 68Ga-PSMA-11 kinetics can be described by an irreversible two-tissue compartment model. An MR-guided method for image-derived blood provides a non-invasive alternative to blood sampling for kinetic modeling studies. SUV showed strong correlation with K i and can be used in routine clinical settings to quantify 68Ga-PSMA-11 uptake.http://link.springer.com/article/10.1186/s13550-020-0594-6Prostate cancerPSMAPET/MRKinetic modelingArterial blood samplingImage-derived input function
collection DOAJ
language English
format Article
sources DOAJ
author Anna Ringheim
Guilherme de Carvalho Campos Neto
Udunna Anazodo
Lumeng Cui
Marcelo Livorsi da Cunha
Taise Vitor
Karine Minaif Martins
Ana Cláudia Camargo Miranda
Marycel Figols de Barboza
Leonardo Lima Fuscaldi
Gustavo Caserta Lemos
José Roberto Colombo Junior
Ronaldo Hueb Baroni
spellingShingle Anna Ringheim
Guilherme de Carvalho Campos Neto
Udunna Anazodo
Lumeng Cui
Marcelo Livorsi da Cunha
Taise Vitor
Karine Minaif Martins
Ana Cláudia Camargo Miranda
Marycel Figols de Barboza
Leonardo Lima Fuscaldi
Gustavo Caserta Lemos
José Roberto Colombo Junior
Ronaldo Hueb Baroni
Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
EJNMMI Research
Prostate cancer
PSMA
PET/MR
Kinetic modeling
Arterial blood sampling
Image-derived input function
author_facet Anna Ringheim
Guilherme de Carvalho Campos Neto
Udunna Anazodo
Lumeng Cui
Marcelo Livorsi da Cunha
Taise Vitor
Karine Minaif Martins
Ana Cláudia Camargo Miranda
Marycel Figols de Barboza
Leonardo Lima Fuscaldi
Gustavo Caserta Lemos
José Roberto Colombo Junior
Ronaldo Hueb Baroni
author_sort Anna Ringheim
title Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
title_short Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
title_full Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
title_fullStr Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
title_full_unstemmed Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
title_sort kinetic modeling of 68ga-psma-11 and validation of simplified methods for quantification in primary prostate cancer patients
publisher SpringerOpen
series EJNMMI Research
issn 2191-219X
publishDate 2020-02-01
description Abstract Background The positron emission tomography (PET) ligand 68Ga-Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA-11) targets the prostate-specific membrane antigen (PSMA), upregulated in prostate cancer cells. Although 68Ga-PSMA-11 PET is widely used in research and clinical practice, full kinetic modeling has not yet been reported nor have simplified methods for quantification been validated. The aims of our study were to quantify 68Ga-PSMA-11 uptake in primary prostate cancer patients using compartmental modeling with arterial blood sampling and to validate the use of standardized uptake values (SUV) and image-derived blood for quantification. Results Fifteen patients with histologically proven primary prostate cancer underwent a 60-min dynamic 68Ga-PSMA-11 PET scan of the pelvis with axial T1 Dixon, T2, and diffusion-weighted magnetic resonance (MR) images acquired simultaneously. Time-activity curves were derived from volumes of interest in lesions, normal prostate, and muscle, and mean SUV calculated. In total, 18 positive lesions were identified on both PET and MR. Arterial blood activity was measured by automatic arterial blood sampling and manual blood samples were collected for plasma-to-blood ratio correction and for metabolite analysis. The analysis showed that 68Ga-PSMA-11 was stable in vivo. Based on the Akaike information criterion, 68Ga-PSMA-11 kinetics were best described by an irreversible two-tissue compartment model. The rate constants K 1 and k 3 and the net influx rate constants K i were all significantly higher in lesions compared to normal tissue (p < 0.05). K i derived using image-derived blood from an MR-guided method showed excellent agreement with K i derived using arterial blood sampling (intraclass correlation coefficient = 0.99). SUV correlated significantly with Ki with the strongest correlation of scan time-window 30–45 min (rho 0.95, p < 0.001). Both K i and SUV correlated significantly with serum prostate specific antigen (PSA) level and PSA density. Conclusions 68Ga-PSMA-11 kinetics can be described by an irreversible two-tissue compartment model. An MR-guided method for image-derived blood provides a non-invasive alternative to blood sampling for kinetic modeling studies. SUV showed strong correlation with K i and can be used in routine clinical settings to quantify 68Ga-PSMA-11 uptake.
topic Prostate cancer
PSMA
PET/MR
Kinetic modeling
Arterial blood sampling
Image-derived input function
url http://link.springer.com/article/10.1186/s13550-020-0594-6
work_keys_str_mv AT annaringheim kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT guilhermedecarvalhocamposneto kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT udunnaanazodo kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT lumengcui kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT marcelolivorsidacunha kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT taisevitor kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT karineminaifmartins kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT anaclaudiacamargomiranda kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT marycelfigolsdebarboza kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT leonardolimafuscaldi kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT gustavocasertalemos kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT joserobertocolombojunior kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
AT ronaldohuebbaroni kineticmodelingof68gapsma11andvalidationofsimplifiedmethodsforquantificationinprimaryprostatecancerpatients
_version_ 1725018239701876736